Deal overview
| Target | AVIDITY BIOSCIENCES INC |
|---|---|
| Bidder | NOVARTIS AG |
| Price | £80.00 Full version or £25.00 Light version |
| Publication Date | Oct 26, 2025 |
| Abstract | On 26 October 2025[+], the quoted Swiss pharmaceutical company Novartis AG ("Novartis") announced a cash offer for Avidity Biosciences, Inc ("Avidity"), a Nasdaq listed biopharmaceutical company focused on a new class of therapeutics enabling RNA delivery to muscle. Novartis would pay US$ 72 per Avidity, which implied an equity value of approximately US$ 12 billion for 100% ... |
| Number of pages (Full version) | 8 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
